HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[A dramatic effect of continuous intra-arterial injected recombinant interleukin-2 immunotherapy on malignant hemangioendothelioma].

Abstract
A malignant hemangioendothelioma (MHE) developed on the frontal scalp of an 83-year-old woman was treated with intralesional injection of recombinant interleukin-2 (rIL-2, TGP-3, Takeda Chemical Industries LTD, Osaka) which had lead the lesion to complete remission for 2 years and 9 months. After the period of the complete remission, the patient developed MHE lesion on the occipital scalp which rapidly enlarged to more than 10 cm in diameter within 7 days, though there was no recurrence of MHE on the frontal scalp at that time. Intra-arterial rIL-2 injection was conducted through the occipital artery which circulates around the tumor lesion, but resulted unsuccessful because of the obstruction of the artery. Continuous intra-arterial rIL-2 injection through bilateral superficial temporal arteries was conducted, and then the tumor lesion came to complete remission on both clinical and histological data. So far, the patient has been showing no local recurrence or metastasis for the period of 8 months. We conclude that continuous intra-arterial rIL-2 injection immunotherapy through superficial temporal arteries is the best way of all the treatment in cases with recurrent MHE located on occipital scalp.
AuthorsM Takano, Y Suzuki, T Asai, M Masuzawa, S Nishiyama
JournalNihon Hifuka Gakkai zasshi. The Japanese journal of dermatology (Nihon Hifuka Gakkai Zasshi) Vol. 101 Issue 7 Pg. 719-25 (Jun 1991) ISSN: 0021-499X [Print] Japan
PMID1942580 (Publication Type: Case Reports, English Abstract, Journal Article)
Chemical References
  • Interleukin-2
  • Recombinant Proteins
Topics
  • Aged
  • Aged, 80 and over
  • Female
  • Hemangioendothelioma (therapy)
  • Humans
  • Injections, Intra-Arterial (methods)
  • Interleukin-2 (administration & dosage, therapeutic use)
  • Neoplasm Recurrence, Local (therapy)
  • Recombinant Proteins (administration & dosage, therapeutic use)
  • Remission Induction
  • Scalp
  • Skin Neoplasms (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: